[REVISION HISTORY]
Creatine research & cancer immunotherapy in US
Updated 1 time since CLSTR started tracking revisions of this situation.
What changed
2026-07-26 10:55 UTC → 2026-07-31 05:18 UTC ·
added
removed
Creatine research and & cancer risk immunotherapy in US
Observational data from analysis of more than 25,000 U.S. adults linked higher dietary creatine intake with to a modest (~5 %) reduction drop in overall cancer incidence, especially particularly among overweight men. Laboratory work from at UCLA has shown that creatine supplementation improves dendritic‑cell function, raises intracellular ATP in tumor‑infiltrating dendritic cells, and, as a new pre‑clinical study confirmed, also serves acts as an energy “backup battery” for tumor‑infiltrating dendritic cells and cytotoxic T cells. By recharging T‑cell energy stores and enhancing cells, boosting intracellular ATP, improving dendritic‑cell survival, creatine helps immune cells persist longer and extending T‑cell activity in nutrient‑poor tumor microenvironments, slowing tumour microenvironments. Pre‑clinical mouse models of melanoma confirmed that dietary creatine slows tumour growth in mice and improving the efficacy of augments checkpoint‑inhibitor therapies. The efficacy. A July 2026 iScience report highlighted higher paper from the same UCLA team reiterated these mechanisms, documenting pronounced expression of the creatine transporter in tumor‑associated tumour‑associated dendritic cells, linking transporter activity to immune efficiency. Across epidemiologic, mechanistic, cells and pre‑clinical findings, demonstrating enhanced T‑cell training and tumour‑killing after creatine appears to supplementation. The authors highlighted the low cost of creatine but stressed that human trials, dosing, and supplement quality must be validated before therapeutic use. Together, epidemiologic, mechanistic and animal‑model evidence suggest creatine could serve as a low‑cost metabolic adjuvant that could to broaden cancer‑immunotherapy responses, though human trials are still needed to confirm safety, optimal dosing, definitive safety and therapeutic benefit. efficacy data in patients remain pending.
Versions
- 2026-07-31 05:18 UTC Creatine research & cancer immunotherapy in US
- 2026-07-26 10:55 UTC Creatine research and cancer risk in US
Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.